Eli Lilly has struck a $5.9 billion deal to partner with Stipple Bio on oncology drug candidates that more precisely target tumor cells.
Founded by Fred Hutch Cancer Center’s Aaron Ring, M.D., Ph.D., and University of California, San Francisco’s Aashish Manglik, M.D., Ph.D., Stipple is built on its Pointillist platform for discovering cell-surface epitopes specific to cancer cells. By operating on the level of epitopes, the biotech aims to develop medicines that are highly specific for tumor cel